DDInter1250 DDInter1676
Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type 2a (IgG2a).
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Muromonab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Muromonab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Muromonab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Muromonab {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Muromonab {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Muromonab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Muromonab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Muromonab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Muromonab may lead to a major life threatening interaction when taken with Natalizumab
Muromonab may lead to a major life threatening interaction when taken with Etanercept